The Role of Microparticles as a Biomarker

Withdrawn before enrolling

Conditions studied: Atypical Hemolytic Uremic Syndrome, Thrombotic Thrombocytopenic Purpura, Microparticles, Microangiopathic Hemolytic Anemia

In brief

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Key facts

Study ID

NCT02626663

Run by

University of Rochester

People needed

0

Starts

2016-07-01

Expected to finish

2022-12-01

Last updated by the study team

2019-02-19

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with MAHA, TTP, and/or aHUS

You may not qualify if…

• Prisoners

Where it is running

• University of Rochester Medical Center — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.